BrainsWay (BWAY) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BWAY shares.
View BWAY analyst ratings or view top-rated stocks.

3 brokerages have issued twelve-month price targets for BrainsWay's shares. Their BWAY share price forecasts range from $3.00 to $12.00. On average, they anticipate the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 58.0% from the stock's current price.
View analysts price targets for BWAY or view top-rated stocks among Wall Street analysts.

BrainsWay's stock was trading at $2.47 at the beginning of 2023. Since then, BWAY stock has increased by 70.9% and is now trading at $4.22.
View the best growth stocks for 2023 here.

BrainsWay saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 82,800 shares, an increase of 268.0% from the August 15th total of 22,500 shares. Based on an average daily volume of 50,000 shares, the days-to-cover ratio is presently 1.7 days.
View BrainsWay's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023.
View our BWAY earnings forecast.

BrainsWay Ltd. (NASDAQ:BWAY) released its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.12. The company had revenue of $7.83 million for the quarter, compared to analysts' expectations of $7.03 million. BrainsWay had a negative net margin of 50.67% and a negative trailing twelve-month return on equity of 29.12%.

Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET).

(BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor served as the underwriter for the IPO.

BrainsWay trades on the NASDAQ under the ticker symbol "BWAY."

BrainsWay's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Worth Venture Partners LLC (1.92%), Psagot Value Holdings Ltd. Israel (0.45%), Citadel Advisors LLC (0.37%), Renaissance Technologies LLC (0.27%) and Good Life Advisors LLC (0.23%).

Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BWAY stock can currently be purchased for approximately $4.22.

BrainsWay (NASDAQ:BWAY) has a market capitalization of $70.05 million and generates $27.18 million in revenue each year. The company earns $-13,350,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

The company employs 134 workers across the globe.

BrainsWay's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The official website for the company is www.brainsway.com. The company can be reached via phone at (722) 582-4030 or via email at hadarl@brainsway.com.